{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:17:01Z","timestamp":1790083021227,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ctrv.2024.102692","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T02:26:13Z","timestamp":1705976773000},"page":"102692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists"],"prefix":"10.1016","volume":"125","author":[{"given":"Marcello","family":"Tucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cosmai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pirovano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Vanessa","family":"Re Sart\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Gallieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102692_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2024.102692_b0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs\u2014Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2024.102692_b0015","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.euf.2017.01.006","article-title":"Variability of Sex Disparities in Cancer Incidence over 30 Years: The Striking Case of Kidney Cancer","volume":"4","author":"Scelo","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ctrv.2024.102692_b0020","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2018.79.1905","article-title":"Epidemiology and Risk Factors for Kidney Cancer","volume":"36","author":"Scelo","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","article-title":"International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality","volume":"67","author":"Znaor","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2024.102692_b0030","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ctrv.2024.102692_b0035","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/oxfordjournals.aje.a009667","article-title":"Population Attributable Risk of Renal Cell Cancer in Minnesota","volume":"148","author":"Benichou","year":"1998","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ctrv.2024.102692_b0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic Germline Variants in 10,389 Adult Cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2024.102692_b0045","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s41598-020-79367-y","article-title":"Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries","volume":"11","author":"Sung","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2024.102692_b0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2018.06.003","article-title":"The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment","volume":"74","author":"Bhindi","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2024.102692_b0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11864-018-0517-1","article-title":"Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma","volume":"19","author":"Gill","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0060","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ctrv.2024.102692_b0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1749-6632.2000.tb06320.x","article-title":"Molecular Basis of Angiogenesis: Role of VEGF and VE-Cadherin","volume":"902","author":"Carmeliet","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2024.102692_b0075","doi-asserted-by":"crossref","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2024.102692_b0080","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102692_b0085","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102692_b0090","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2021.39.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426","volume":"39","author":"Rini","year":"2021","journal-title":"Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO)"},{"key":"10.1016\/j.ctrv.2024.102692_b0095","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102692_b0100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0105","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102692_b0110","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102692_b0120","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0125","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102692_b0130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4501","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426","volume":"41","author":"Rini","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0135","doi-asserted-by":"crossref","unstructured":"Erratum: Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial. Journal of Clinical Oncology 2023;41:3767\u20133767. https:\/\/doi.org\/10.1200\/JCO.23.00901.","DOI":"10.1200\/JCO.23.00901"},{"key":"10.1016\/j.ctrv.2024.102692_b0140","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1200\/JCO.2023.41.6_suppl.603","article-title":"Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial","volume":"41","author":"Burotto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0145","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0150","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2023.41.16_suppl.4502","article-title":"Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"41","author":"Motzer","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0155","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102692_b0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2407-11-105","article-title":"Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy","volume":"11","author":"Porta","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102692_b0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40620-016-0311-8","article-title":"Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)","volume":"30","author":"Cosmai","year":"2017","journal-title":"J Nephrol"},{"key":"10.1016\/j.ctrv.2024.102692_b0170","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00345-012-1001-3","article-title":"Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis","volume":"31","author":"Tsao","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.ctrv.2024.102692_b0175","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/HYPERTENSIONAHA.122.17947","article-title":"Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension\u2014Mechanisms and Mitigation","volume":"80","author":"Butel-Simoes","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.ctrv.2024.102692_b0180","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ctrv.2024.102692_b0185","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11912-022-01224-0","article-title":"VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications","volume":"24","author":"Camarda","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2024.102692_b0190","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ctrv.2024.102692_b0195","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/life13020366","article-title":"Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors","volume":"13","author":"Mihalcea","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.ctrv.2024.102692_b0200","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ctrv.2024.102692_b0205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine Kinase Inhibitor-Induced Hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2024.102692_b0210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14712598.2019.1594770","article-title":"Acute blood pressure elevation associated with biological therapies for cancer: a focus on VEGF signaling pathway inhibitors","volume":"19","author":"Pucci","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ctrv.2024.102692_b0215","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ctrv.2024.102692_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11040640","article-title":"Nephrotoxicity of anti-angiogenic therapies","volume":"11","author":"Van Wynsberghe","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.ctrv.2024.102692_b0225","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fotivda-epar-product-information_it.pdf n.d."},{"key":"10.1016\/j.ctrv.2024.102692_b0230","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102692_b0235","doi-asserted-by":"crossref","unstructured":"Bonilla M, Gudsoorkar P, Wanchoo R, Herrmann SM, Jhaveri KD. Onconephrology 2022: An Update. Kidney360 2023;4:258\u201371. https:\/\/doi.org\/10.34067\/KID.0001582022.","DOI":"10.34067\/KID.0001582022"},{"key":"10.1016\/j.ctrv.2024.102692_b0240","doi-asserted-by":"crossref","unstructured":"Person F, Rinschen MM, Brix SR, Wulf S, Noriega M de las M, Fehrle W, et al. Bevacizumab-associated glomerular microangiopathy. Modern Pathology 2019;32:684\u2013700. https:\/\/doi.org\/10.1038\/s41379-018-0186-4.","DOI":"10.1038\/s41379-018-0186-4"},{"key":"10.1016\/j.ctrv.2024.102692_b0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.ctrv.2024.102692_b0250","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/his.13716","article-title":"Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy","volume":"73","author":"Pfister","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2024.102692_b0255","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1186\/s12885-021-08622-w","article-title":"Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients","volume":"21","author":"Masaki","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102692_b0260","article-title":"Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer. Front","volume":"13","author":"Shibutani","year":"2023","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0265","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102692_b0270","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lenvima-epar-product-information_it.pdf 2023."},{"key":"10.1016\/j.ctrv.2024.102692_b0275","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cabometyx-epar-product-information_it.pdf 2023."},{"key":"10.1016\/j.ctrv.2024.102692_b0280","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inlyta-epar-product-information_it.pdf 2023."},{"key":"10.1016\/j.ctrv.2024.102692_b0285","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sutent-epar-product-information_it.pdf n.d."},{"key":"10.1016\/j.ctrv.2024.102692_b0290","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2215\/CJN.05610522","article-title":"How I Manage Hypertension and Proteinuria Associated with VEGF Inhibitor","volume":"18","author":"Rashidi","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ctrv.2024.102692_b0295","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00280-021-04260-y","article-title":"Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function","volume":"87","author":"Mielczarek","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2024.102692_b0300","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102692_b0305","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ctrv.2024.102692_b0310","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ctrv.2024.102692_b0315","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0320","article-title":"The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity","volume":"9","author":"Moss","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ctrv.2024.102692_b0325","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2024.102692_b0330","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ctrv.2024.102692_b0335","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ctrv.2024.102692_b0340","doi-asserted-by":"crossref","unstructured":"Franzin R, Netti GS, Spadaccino F, Porta C, Gesualdo L, Stallone G, et al. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? Front Immunol 2020;11. https:\/\/doi.org\/10.3389\/fimmu.2020.574271.","DOI":"10.3389\/fimmu.2020.574271"},{"key":"10.1016\/j.ctrv.2024.102692_b0345","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0350","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2024.102692_b0355","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ackd.2021.07.006","article-title":"Immunotherapy-Related Acute Kidney Injury","volume":"28","author":"Manohar","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ctrv.2024.102692_b0360","doi-asserted-by":"crossref","first-page":"e000750","DOI":"10.1136\/jitc-2020-000750","article-title":"Checkpoint inhibitor-related renal vasculitis and use of rituximab","volume":"8","author":"Mamlouk","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2024.102692_b0365","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.kint.2018.11.009","article-title":"Interstitial nephritis in immune checkpoint inhibitor therapy","volume":"96","author":"Manohar","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ctrv.2024.102692_b0370","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ctrv.2024.102692_b0375","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euf.2022.07.003","article-title":"Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System","volume":"9","author":"Matsumoto","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ctrv.2024.102692_b0380","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","article-title":"First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis","volume":"4","author":"Quhal","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0385","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.3390\/curroncol29100533","article-title":"Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice","volume":"29","author":"Dri","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0390","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41416-020-0949-9","article-title":"Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events","volume":"123","author":"Gr\u00fcnwald","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102692_b0395","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2021.12.007","article-title":"Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis","volume":"37","author":"Bosma","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.ctrv.2024.102692_b0400","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0405","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf. 2023."},{"key":"10.1016\/j.ctrv.2024.102692_b0410","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_it.pdf 2023."},{"key":"10.1016\/j.ctrv.2024.102692_b0415","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2022.03.031","article-title":"Immune checkpoint inhibitor associated renally limited thrombotic microangiopathy \u2013 a clinical dilemma","volume":"169","author":"Badra","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102692_b0420","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.30652","article-title":"Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases","author":"Alqurashi","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.ctrv.2024.102692_b0425","article-title":"Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2024.102692_b0430","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2174\/1389200220666190402143125","article-title":"Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure","volume":"20","author":"Fujita","year":"2019","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ctrv.2024.102692_b0435","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/j.ackd.2021.12.002","article-title":"Cancer Drug Dosing in Chronic Kidney Disease and Dialysis","volume":"29","author":"Shirali","year":"2022","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ctrv.2024.102692_b0440","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2019.05.016","article-title":"Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)\/Societa\u2019 Italiana di Nefrologia (SIN) multidisciplinary consensus position paper","volume":"140","author":"Silvestris","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2024.102692_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103169","article-title":"Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature","volume":"157","author":"Mroue","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2024.102692_b0450","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ctrv.2024.102692_b0455","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2217\/imt-2016-0099","article-title":"Immune checkpoint inhibitors renal side effects and management","volume":"8","author":"El","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctrv.2024.102692_b0460","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1159\/000519855","article-title":"Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report","volume":"14","author":"Katsumata","year":"2021","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ctrv.2024.102692_b0465","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/votrient-epar-product-information_it.pdf n.d."},{"key":"10.1016\/j.ctrv.2024.102692_b0470","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1681\/ASN.2018090906","article-title":"Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant","volume":"30","author":"Au","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ctrv.2024.102692_b0475","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cncr.31782","article-title":"Survival after a cancer diagnosis among solid organ transplant recipients in the United States","volume":"125","author":"D\u2019Arcy","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102692_b0480","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/ijc.32585","article-title":"Cancer mortality in kidney transplant recipients: An Australian and New Zealand population-based cohort study, 1980\u20132013","volume":"146","author":"Rosales","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2024.102692_b0485","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.kint.2020.07.025","article-title":"Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation","volume":"99","author":"Raynaud","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ctrv.2024.102692_b0490","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ekir.2019.11.015","article-title":"Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients","volume":"5","author":"Manohar","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ctrv.2024.102692_b0495","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ctrv.2024.102692_b0500","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:31:33Z","timestamp":1759656693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":100,"alternative-id":["S0305737224000100"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102692","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102692"}}